Genmab A/S (GNMSF)
PNK: GNMSF
· Real-Time Price · USD
205.10
0.12 (0.06%)
At close: May 01, 2025, 2:19 PM
0.06% (1D)
| Bid | 205.1 |
| Market Cap | 12.61B |
| Revenue (ttm) | 21.53B |
| Net Income (ttm) | 7.84B |
| EPS (ttm) | 18.45 |
| PE Ratio (ttm) | 11.12 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 220.24 |
| Volume | 9 |
| Avg. Volume (20D) | 1,957 |
| Open | 208.80 |
| Previous Close | 204.98 |
| Day's Range | 205.10 - 208.80 |
| 52-Week Range | 170.00 - 305.09 |
| Beta | 0.96 |
About GNMSF
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esoph...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 5, 2010
Employees 2,682
Stock Exchange PNK
Ticker Symbol GNMSF
Website https://www.genmab.com
